Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics, Inc. reported that Chief Technical Operations Officer Neil Gregory Almstead sold a total of 52,003 shares of common stock in open‑market transactions on 2026-04-01 at prices around $69 per share.
After these sales, he directly holds 60,137 shares of PTC Therapeutics common stock and indirectly holds 2,737 shares through his spouse. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
PTCT submitted a Form 144 notice reporting proposed resale activity in its Common Stock. The filing lists 829 shares tied to a restricted stock vesting on 04/01/2026 as securities to be sold. The filing also itemizes open-market dispositions by Lee S. Golden during the prior three months: 1,340, 642, 866, 2,484, and 10,000 shares with corresponding proceeds shown on the form.
PTCT insiders reported multiple restricted-stock vesting events and subsequent Rule 144 sales. The excerpt lists scheduled restricted-stock vesting entries across 2016–2025 and shows recent open-market sales by Neil G. Almstead and Zheng Y. Almstead on specific dates in 2026 with per-trade share counts and proceeds.
PTC Therapeutics Inc: The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of PTC Therapeutics common stock. The filing states Vanguard disaggregated certain subsidiaries after an internal realignment effective January 12, 2026 in reliance on SEC Release No. 34-39538. The amendment is signed by Ashley Grim on 03/27/2026.
PTC Therapeutics director Jessica Caroline Chutter received new equity awards. On March 24, 2026, she was granted stock options for 3,475 and 2,896 shares of common stock at an exercise price of $64.54 per share, expiring on March 23, 2036.
She also received 4,000 restricted stock units that vest in three equal annual installments starting March 24, 2027, and 3,333 restricted stock units that vest with 1,000 shares on June 2, 2026 and 2,333 shares on January 2, 2027. All transactions reflect compensation-related grants rather than open-market purchases or sales.
PTC Therapeutics, Inc. director Jessica Caroline Chutter filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. The filing does not list any stock transactions or holdings details in the provided data, and serves as a baseline disclosure of her insider status.
PTC Therapeutics has appointed veteran biotechnology investment banker Jessica Chutter to its board of directors, effective March 24, 2026, filling a vacancy. She will serve as a Class I director with a term ending at the 2026 annual meeting of stockholders.
Chutter recently retired from Morgan Stanley after more than 40 years in healthcare investment banking and has advised on about $80 billion of capital raising and $85 billion of strategic transactions. As compensation, she will receive a $50,000 annual cash retainer plus initial and pro-rated 2026 equity grants totaling 6,371 stock options and 7,333 restricted stock units, vesting over multi-year schedules.
PTC Therapeutics CEO Matthew B. Klein reported routine equity compensation activity and a related tax sale. He acquired 12,500 shares of common stock through earned restricted stock units tied to performance-based awards granted in December 2024. The company’s compensation committee certified achievement of a pre-established milestone as of March 11, 2026, causing these units to be earned.
Of the earned units, 6,500 shares vested immediately on March 11, 2026, with the remaining 6,500 scheduled to vest on March 11, 2027. On March 12, 2026, 2,662 shares were automatically sold at $64.08 per share under a pre-set “sell to cover” election to satisfy tax withholding obligations. Following these transactions, Klein directly holds 396,920 shares of PTC Therapeutics common stock.
PTC Therapeutics director Stephanie Okey exercised stock options and sold shares in a pre-planned transaction. On March 10, 2026, she exercised options to acquire 15,167 shares of common stock at an exercise price of $33.63 per share.
On the same date, she sold 15,167 common shares in open-market transactions at a sale price of $70.00 per share pursuant to a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, she holds 8,000 shares of PTC Therapeutics common stock directly.
Matthew Klein reported proposed and recent sales of Common Stock. The filing lists a proposed sale of 2,662 shares on 03/11/2026 tied to restricted stock vesting. The filing also records multiple sales in the prior three months, including 8,089 shares on 12/30/2025 and 7,371 shares on 02/18/2026, with dollar amounts shown for each trade.